Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: A double-blind, randomized, placebo-controlled study in patients with previous poor response to sumatriptan 50 mg

Current Medical Research and Opinion

Volumn 21, Issue 10, 2005, Pages 1603-1610

  Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Almotriptan; Efficacy; Migraine; Non response; Sumatriptan; Triptans

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; PLACEBO; SUMATRIPTAN;

ADULT; AGED; ANALGESIA; ARTICLE; BITTER TASTE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EMOTIONAL DISORDER; EYE DISEASE; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NERVOUSNESS; PAIN ASSESSMENT; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TASTE DISORDER; THORAX PAIN; TREMBLING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; SEROTONIN AGONISTS; SUMATRIPTAN; TRYPTAMINES;

EID: 27144525550     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65448     Document Type: Article

References (19)

1. Dodick DW. Acute and prophylactic management of migraine. Clin Cornerstone 2001;4:36-52
2. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Invest Drugs 2001;10:1831-45
3. Silberstein SD. Migraine. Lancet 2004;363:381-91
4. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-87
5. Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40:189-205
6. Rapoport AM, Tepper SJ. Triptans are all different. Arch Neurol 2001;58:1479-80
7. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75
8. Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache 2005;45:874-82
9. Mathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of non-responders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 2000;40:464-5
10. Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000;40:513-20
11. Farkkila M, Olesen J, Dahlöf C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:463-71
12. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005;45:156-62
13. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-96
14. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999;39(Suppl 2):S20-S26
15. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine [2nd ed.]. Cephalalgia 2000;20:765-86
16. Whitaker JN. Triptans for migraine headache: therapeutic progress meets a heterogeneous patient response. Arch Neurol 2001;58:1482-3
17. Meckling SK, Becker WJ, Rose MS, Dalby JT. Sumatriptan responsiveness and clinical, psychiatric and psychologic features in migraine patients. Can J Neurol Sci 2001;28:313-8
18. Dahlöf CG, Lipton RB, McCarroll KA, et al. Within-patient consistency of response of rizatriptan for treating migraine. Neurology 2000;55:1511-6
19. Goadsby PJ. Serotonin receptors and the acute attack of migraine. Clin Neurosci 1998;5:18-23